The UK-based company has a clinically validated T-SIGn viral vector platform which can deliver multiple transgene payloads capable of reprogramming both primary and metastatic solid tumors.

PsiOxus also has a rapidly expanding pipeline of T-SIGn monotherapy and combination products that have demonstrated consistent safety profiles and preliminary evidence of efficacy based on biomarker data and other clinical surrogates.